On October 19, 2021, "Weitai Medical," a portfolio company backed by sub-funds invested in by Yuanhe Chenchun Management's flagship fund—including ChenDe Capital, Eli Lilly Asia Fund, and Qiming Venture Partners—successfully listed on the Hong Kong stock exchange under the stock code 2235.HK.

Founded in 2011, Weitai Medical is dedicated to the research, development, and service provision of medical devices in the fields of diabetes monitoring and treatment. We strive to optimize diabetes management worldwide through cutting-edge technology products and innovative service concepts, helping diabetic patients lead healthier, happier lives.

Through years of development, Weitai has built a comprehensive diabetes management product line centered around the "Equil Patch-Type Insulin Pump System" and the "AiDEX Continuous Glucose Monitoring System," with product performance reaching world-class standards.

The Equil patch-type insulin pump system is the world’s only patch-based insulin pump system approved for marketing simultaneously in both China and Europe. Meanwhile, the AiDEX G7 continuous glucose monitoring system is the second globally to successfully achieve commercialization as a "14-day, calibration-free, real-time" dynamic glucose monitoring solution.

Currently, Weitai Medical has successfully positioned itself on both the "drug therapy" and "blood glucose monitoring" fronts, becoming the only company globally to simultaneously offer both a patch-type insulin pump and a calibration-free continuous glucose monitoring system.

By innovating and integrating diabetes treatment and monitoring technologies, Weitai Medical has redefined diabetes management models in China and globally. With robust R&D, manufacturing, and commercialization capabilities, Weitai Medical will continue to drive comprehensive, end-to-end diabetes care in the future, creating a closed-loop system that seamlessly integrates monitoring, treatment, and chronic disease management.